Guidance was reaffirmed on Monday in conjunction with investor meetings and a webcast on January 10. The company expects its full-year 2022 Adjusted EPS to be at the high end of the guidance range primarily due to certain non-operating items, including a lower share count. In addition, the Company expects that it will exceed its full-year 2022 revenue guidance range of $309B-$314B, consensus $314.81B, and will reaffirm its full-year 2022 adjusted operating income guidance range of $17.5B-$17.6B and its full-year 2022 cash flow from operations guidance range of $13.5B-$14.5B.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CVS:
- Takeout report adds ‘intrigue’ to Oak Street story, says Piper Sandler
- CVS (NYSE:CVS) Reportedly in Talks to Buy Oak Street for over $10B
- CVS Health exploring acquisition of Oak Street Health, Bloomberg reports
- Oak Street Health jumps 26% after Bloomberg reports potential acquisition by CVS
- NY, NC opportunities could be 1% tailwind to CVS EPS, says Wells Fargo
